A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity

@article{OkadaIwabu2013ASA,
  title={A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity},
  author={Miki Okada-Iwabu and Toshimasa Yamauchi and Masato Iwabu and Teruki Honma and Ken-ichi Hamagami and Koichi Matsuda and Mamiko Yamaguchi and Hiroaki Tanabe and Tomomi Kimura-Someya and Mikako Shirouzu and Hitomi Ogata and Kumpei Tokuyama and Kohjiro Ueki and Tetsuo Nagano and Akiko Tanaka and Shigeyuki Yokoyama and Takashi Kadowaki},
  journal={Nature},
  year={2013},
  volume={503},
  pages={493-499}
}
Adiponectin secreted from adipocytes binds to adiponectin receptors AdipoR1 and AdipoR2, and exerts antidiabetic effects via activation of AMPK and PPAR-α pathways, respectively. Levels of adiponectin in plasma are reduced in obesity, which causes insulin resistance and type 2 diabetes. Thus, orally active small molecules that bind to and activate AdipoR1 and AdipoR2 could ameliorate obesity-related diseases such as type 2 diabetes. Here we report the identification of orally active synthetic… 
Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity
TLDR
AdipoRon ameliorated diabetes associated with obesity as well as to increase exercise endurance, thus prolonging shortened lifespan of obese mice fed on a high fat diet.
AdipoR agonist increases insulin sensitivity and exercise endurance in AdipoR-humanized mice
TLDR
It is shown that overexpressing human AdipoR1 in the muscles of diabetic mice increased insulin sensitivity and exercise endurance, suggesting a possible route for future clinical therapies.
Drug development research for novel adiponectin receptor-targeted antidiabetic drugs contributing to healthy longevity
TLDR
It is expected that increasing insight into AdipoR signaling will facilitate the structure-based optimization of candidate small-molecule AdipeR-activating compounds for human use as well as the development of molecularly targeted and calorie-limiting/exercise-mimicking agents for lifestyle-linked diseases.
The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.
  • Yaeni Kim, J. Lim, C. Park
  • Biology, Medicine
    Journal of the American Society of Nephrology : JASN
  • 2018
TLDR
Results show that AdipoRon ameliorates GEC and podocyte injury by activating the intracellular Ca2+/LKB1-AMPK/PPARα pathway, suggesting its efficacy for treating type 2 diabetes-associated DN.
Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease
  • Yaeni Kim, C. Park
  • Biology, Medicine
    International journal of molecular sciences
  • 2019
TLDR
AdipoRon, an orally active synthetic adiponectin receptor agonist is proposed as a promising drug for restoration of DKD without inducing systemic adverse effects.
Orally Active Osteoanabolic Agent GTDF Binds to Adiponectin Receptors, With a Preference for AdipoR1, Induces Adiponectin-Associated Signaling, and Improves Metabolic Health in a Rodent Model of Diabetes
TLDR
The discovery and characterization of 6-C-β-d-glucopyranosyl-(2S,3S)-(+)-5,7,3′,4′-tetrahydroxydihydroflavonol (GTDF) as an orally active adiponectin mimetic provides a promising therapeutic tool for the treatment of metabolic diseases.
Discovery of a novel potent peptide agonist to adiponectin receptor 1
TLDR
The findings suggest that AdipoRs’ agonists could be developed into a potential therapeutic agent for metabolic diseases, such as diabetes mellitus, especially for type II diabetes, a long-term metabolic disorder characterized by high blood sugar, insulin resistance, and relative lack of insulin.
Modulation of adiponectin receptors AdipoR1 and AdipoR2 by phage display-derived peptides in in vitro and in vivo models
TLDR
An AdipoR1/Adipo R2-targeted peptide that modulates adiponectin signalling pathways and has therapeutic relevance for T2D and obesity associated pathologies is developed.
Possible new therapeutic approach for obesity-related diseases: Role of adiponectin receptor agonists
TLDR
A Japanese team of researchers has screened and identified an orally active compound that binds to and activates the adiponectin receptor 1 and AdipoR2 receptors that are named AdipRon, which ameliorates insulin resistance and glucose intolerance in obese animal models, and also extends the shortened lifespan of diabetic obese mice.
...
...

References

SHOWING 1-10 OF 48 REFERENCES
Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions
TLDR
Adenovirus-mediated expression of AdipoR1 and R2 in the liver of Lepr−/− mice increased AMP-activated protein kinase (AMPK) activation and peroxisome proliferator-activated receptor (PPAR)-α signaling pathways, respectively, and abolished adiponectin binding and actions, leading to insulin resistance and marked glucose intolerance in vivo.
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
TLDR
The cloning of complementary DNAs encoding adiponectin receptors 1 and 2 by expression cloning supports the conclusion that they serve as receptors for globular and full-length adiponECTin, and that they mediate increased AMP kinase and PPAR-α ligand activities, as well as fatty-acid oxidation and glucose uptake by adiponectionin.
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
TLDR
It is concluded that decreased adiponectin is implicated in the development of insulin resistance in mouse models of both obesity and lipoatrophy and that the replenishment of adiponECTin might provide a novel treatment modality for insulin resistance and type 2 diabetes.
Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis*
TLDR
It is shown that replenishment of globular adiponectin may provide a novel treatment modality for both type 2 diabetes and atherosclerosis, and this is the first demonstration that globular leptin can protect against Atherosclerosis in vivo.
Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1
TLDR
Evidence is provided that adiponectin induces extracellular Ca2+ influx by AdipoR1, which was necessary for subsequent activation of Ca2-/calmodulin-dependent protein kinase kinase β (CaMKKβ), AMPK and SIRT1, increased expression and decreased acetylation of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1 α), and increased mitochondria in myocytes.
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
TLDR
It is proposed that obesity-related insulin resistance is, at least in part, a chronic inflammatory disease initiated in adipose tissue, and that macrophage-related inflammatory activities may contribute to the pathogenesis of obesity-induced insulin resistance.
Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity*
TLDR
It is demonstrated that changes in SA in a number of type 2 diabetic cohorts serve as a quantitative indicator of improvements in insulin sensitivity obtained during TZD treatment, whereas changes in total serum adiponectin levels do not correlate well at the individual level.
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
TLDR
It is shown that phosphorylation and activation of the 5′-AMP-activated protein kinase (AMPK) are stimulated with globular and full-length Ad in skeletal muscle and only with full- lengths Ad in the liver, indicating that stimulation of glucose utilization and fatty-acid oxidation by Ad occurs through activation of AMPK.
AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*)
TLDR
The tissue-specific expression of a putative secreted protein suggests that this factor may function as a novel signaling molecule for adipose tissue.
Macrophages, inflammation, and insulin resistance.
TLDR
Strategies focused on inhibiting the inflammation/insulin resistance axis that otherwise preserve essential innate immune functions may hold promise for therapeutic intervention.
...
...